Featured Research

from universities, journals, and other organizations

Can Cancer Causing Compounds Be Cut From Tobacco? Gene 'Knockout' Floors Tobacco Carcinogen

Date:
March 19, 2008
Source:
North Carolina State University
Summary:
In large-scale field trials, scientists have shown that silencing a specific gene in burley tobacco plants significantly reduces harmful carcinogens in cured tobacco leaves. The finding could lead to tobacco products -- especially smokeless products -- with reduced amounts of cancer-causing agents. Researchers stress that the best way for people to avoid the risks associated with tobacco use is to avoid using tobacco products.

In large-scale field trials, scientists from North Carolina State University have shown that silencing a specific gene in burley tobacco plants significantly reduces harmful carcinogens in cured tobacco leaves.

The finding could lead to tobacco products – especially smokeless products – with reduced amounts of cancer-causing agents.

NC State's Dr. Ralph Dewey, professor of crop science, and Dr. Ramsey Lewis, assistant professor of crop science, teamed with colleagues from the University of Kentucky to knock out a gene known to turn nicotine into nornicotine. Nornicotine is a precursor to the carcinogen N-nitrosonornicotine (NNN). Varying percentages of nicotine are turned into nornicotine while the plant ages; nornicotine converts to NNN as the tobacco is cured, processed and stored.

The field tests in Kentucky, Virginia and North Carolina compared cured burley tobacco plants with the troublesome gene silenced and "control" plant lines with normal levels of gene expression. The researchers found a six-fold decrease in carcinogenic NNN in the genetically modified tobacco plants, as well as a 50 percent overall reduction in the class of harmful compounds called TSNAs, or tobacco-specific nitrosamines. TSNAs are reported to be among the most important tobacco-related compounds implicated in various cancers in laboratory experiments, Lewis said.

Lewis and Dewey stress that the best way for people to avoid the risks associated with tobacco use is to avoid using tobacco products. But their findings show that targeted gene silencing can work as well in the field as it does on the lab bench.

"Creating a tobacco plant with fewer or no harmful compounds may also help with tobacco plants that are being used to create pharmaceuticals or other high-value products," Dewey said.

To get initial lines of plants with the troublesome gene silenced, the NC State researchers used a technique called RNA interference in which genetic engineering was used to introduce a gene that inhibits the demethylase gene function into the tobacco plant.

Dewey and Lewis have since developed tobacco lines with the same effect without using genetic engineering. They randomly inserted chemical changes, or mutations, into the tobacco genome of burley tobacco plants. They then searched for plants in which the nicotine demethylase gene was permanently impaired. The researchers are currently working to transfer this mutation to widely used tobacco varieties.

Dewey and Lewis add that nothing else in the plant changed – growth or resistance to insects or disease, for example – after they knocked out this specific gene.

While Lewis believes that varieties of burley tobacco with a silenced demethylase gene will exist within the next few years, the NC State researchers say burley tobacco has a number of other targets for their gene silencing method.

The research is sponsored by Philip Morris USA. Philip Morris USA, a part of Altria Group, Inc., is a leading cigarette manufacturer in the U.S.

Journal reference: Ramsey S. Lewis and Ralph E. Dewey, North Carolina State University; Anne M. Jack, Lily Gavilano, Balazs Siminszky and Lowell Bush, University of Kentucky; Jerry Morris, Vincent Robert and Alec Hayes, Philip Morris USA."RNA Interference (RNAi)-Induced Suppression of Nicotine Demethylase Activity Reduces Levels of a Key Carcinogen in Cured Tobacco Leaves" Online Feb. 14 in Plant Biotechnology Journal


Story Source:

The above story is based on materials provided by North Carolina State University. Note: Materials may be edited for content and length.


Cite This Page:

North Carolina State University. "Can Cancer Causing Compounds Be Cut From Tobacco? Gene 'Knockout' Floors Tobacco Carcinogen." ScienceDaily. ScienceDaily, 19 March 2008. <www.sciencedaily.com/releases/2008/03/080318110336.htm>.
North Carolina State University. (2008, March 19). Can Cancer Causing Compounds Be Cut From Tobacco? Gene 'Knockout' Floors Tobacco Carcinogen. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2008/03/080318110336.htm
North Carolina State University. "Can Cancer Causing Compounds Be Cut From Tobacco? Gene 'Knockout' Floors Tobacco Carcinogen." ScienceDaily. www.sciencedaily.com/releases/2008/03/080318110336.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins